Physician profile
Niloufar Guiv
NPI 1124028345
$2,632.54
in general payments reported to CMS, 2019-2025
19 companies · $816 in 2025
The $816 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $378 · 2020: $112 · 2021: $153 · 2022: $52.91 · 2023: $409 · 2024: $711 · 2025: $816.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,936.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,936.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $435.77 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $431.57 | 2024-2025 | Voquezna |
| Allergan, INC. | $301.86 | 2019 | |
| Janssen Biotech, INC. | $248.51 | 2023-2025 | Tremfya, Stelara |
| Pfizer INC. | $207.95 | 2023-2025 | |
| Genzyme Corporation | $178.16 | 2023-2025 | |
| Madrigal Pharmaceuticals | $145.03 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $126.05 | 2024 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $122.11 | 2024 | Zeposia |
| Janssen Scientific Affairs, LLC | $94.74 | 2020 | |
| Ironwood Pharmaceuticals, INC | $72.49 | 2020-2024 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.54 | 2023-2025 | Xifaxan, Trulance |
| Celgene Corporation | $36.71 | 2023 | Zeposia |
| Capsovision, INC. | $36.09 | 2025 | Capsocam Plus |
| Ardelyx, INC. | $32.05 | 2025 | Ibsrela |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $30.79 | 2019 | |
| Novo Nordisk INC | $28.71 | 2025 | Wegovy |
| Gilead Sciences, INC. | $19.77 | 2023 | |
| Intercept Pharmaceuticals, INC. | $19.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Niloufar Guiv listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.